249 related articles for article (PubMed ID: 17530014)
1. Rituximab therapy in malignant lymphoma.
Coiffier B
Oncogene; 2007 May; 26(25):3603-13. PubMed ID: 17530014
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody as therapy for malignant lymphomas.
Coiffier B
C R Biol; 2006 Apr; 329(4):241-54. PubMed ID: 16644494
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
5. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
Traullé C; Coiffier BB
Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002
[TBL] [Abstract][Full Text] [Related]
6. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Gisselbrecht C
Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and chemotherapy in diffuse large B-cell lymphoma.
Sonet A; Bosly A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):719-26. PubMed ID: 19496708
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.
Hagemeister FB
Clin Adv Hematol Oncol; 2003 Feb; 1(2):120-5. PubMed ID: 16224391
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
11. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Rummel MJ
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
14. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
15. [Current treatment for malignant lymphomas].
Usui N
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2191-9. PubMed ID: 18079619
[TBL] [Abstract][Full Text] [Related]
16. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
Reiter A; Klapper W
Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
[TBL] [Abstract][Full Text] [Related]
18. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
19. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
